Canada markets closed

Processa Pharmaceuticals, Inc. (PCSA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.1500-0.2800 (-11.52%)
At close: 04:00PM EDT
2.0500 -0.10 (-4.65%)
After hours: 05:40PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.4300
Open2.1950
Bid2.0700 x 100
Ask2.1500 x 400
Day's Range2.0200 - 2.3500
52 Week Range1.4000 - 18.0000
Volume1,825,716
Avg. Volume1,515,795
Market Cap6.14M
Beta (5Y Monthly)0.52
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial

    NGC-Cap demonstrated greater 5-FU exposure than monotherapy capecitabine at a significantly lower dose with a favorable clinical safety profile NGC-Cap holds potential for improved efficacy in more patients due to an increase in distribution of 5-FU to cancer cells Phase 1b study final results to be released upon database lock HANOVER, Md., April 11, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focus

  • GlobeNewswire

    Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

    HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that George Ng, Chief Executive Officer, will present a corporate update at the MedInvest Biotech and Pharma Investor Conference. David Young, Processa’s President of Research & Developm

  • GlobeNewswire

    Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

    HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that the Company will have two posters at the American Association for Cancer Research Annual Meeting 2024 in San Diego from April 5-10, 2024. David Young, PharmD, Ph.D., President of Re